Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib

CPT: Pharmacometrics & Systems Pharmacology
T LuJ Y Jin

Abstract

Vismodegib, approved for the treatment of advanced basal cell carcinoma, has shown unique pharmacokinetic (PK) nonlinearity and binding to α1-acid glycoprotein (AAG) in humans. A semi-mechanism-based population pharmacokinetic (PopPK) model was developed from a meta-dataset of 225 subjects enrolled in five clinical studies to quantitatively describe the clinical PK of vismodegib and identify sources of interindividual variability. Total and unbound vismodegib were analyzed simultaneously, together with time-varying AAG data. The PK of vismodegib was adequately described by a one-compartment model with first-order absorption, first-order elimination of unbound drug, and saturable binding to AAG with fast-equilibrium. The variability of total vismodegib concentration at steady-state was predominantly explained by the range of AAG level. The impact of AAG on unbound concentration was clinically insignificant. Various approaches were evaluated for model validation. The semi-mechanism-based PopPK model described herein provided insightful information on the nonlinear PK and has been utilized for various clinical applications.

References

Jun 1, 1997·Journal of Clinical Pharmacology·E I Ette
Apr 24, 1999·Computer Methods and Programs in Biomedicine·J ParkeB G Charles
Nov 5, 1999·Journal of Vascular Surgery·K Ouriel
Aug 10, 2001·Drug Metabolism Reviews·Z H Israili, P G Dayton
Mar 22, 2002·Clinical Pharmacology and Therapeutics·Leslie Z Benet, Betty-ann Hoener
May 11, 2004·Endocrinology·Lian FanWade Bushman
Sep 24, 2005·Pharmaceutical Research·Donald E Mager, Wojciech Krzyzanski
Jul 18, 2006·British Journal of Clinical Pharmacology·Lorraine D RalphAlison H Thomson
Jul 18, 2006·British Journal of Clinical Pharmacology·N WidmerT Buclin
Jul 17, 2007·Nature Medicine·Christine DierksMarkus Warmuth
Aug 30, 2008·Nature·Robert L YauchFrederic J de Sauvage
Nov 14, 2008·Journal of Pharmacokinetics and Pharmacodynamics·Leonid GibianskyPeiming Ma
May 16, 2009·Trends in Pharmacological Sciences·Suzie J Scales, Frederic J de Sauvage
Aug 4, 2009·The AAPS Journal·Radojka M Savic, Mats O Karlsson
Sep 4, 2009·The New England Journal of Medicine·Charles M RudinJennifer A Low
Sep 4, 2009·The New England Journal of Medicine·Daniel D Von HoffJennifer A Low
Feb 23, 2010·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·X DingC E C A Hop
Feb 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard A GrahamPatricia M Lorusso
Feb 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LoRussoDaniel D Von Hoff
Feb 9, 2011·The AAPS Journal·Martin BergstrandMats O Karlsson
Feb 16, 2011·Current Topics in Medicinal Chemistry·Xingrong LiuCornelis E C A Hop
May 24, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Richard A GrahamCornelis E C A Hop
Jul 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LorussoRichard A Graham
Mar 22, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael AxelsonRichard Pazdur

❮ Previous
Next ❯

Citations

May 20, 2017·Cancer Chemotherapy and Pharmacology·Ghassan K Abou-AlfaRichard A Graham
Jan 29, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·R DummerR J J Grob
Jul 22, 2018·Drugs·James E Frampton, Nicole Basset-Séguin
Nov 17, 2020·Frontiers in Oncology·Gabriella BrancaccioGiuseppe Argenziano

❮ Previous
Next ❯

Methods Mentioned

BETA
equilibrium dialysis

Clinical Trials Mentioned

NCT00607724
NCT00968981
NCT00833417
NCT00991718
NCT01173536
NCT01201915

Software Mentioned

ICON
Intel Fortran Compiler
PLUS
NONMEM
PopPK

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.